Top

Published in:

01-08-2009 | Hepatobiliary and Pancreatic Tumors

Clinical Significance of Microvessel Count in Patients with Metastatic Liver Cancer Originating from Colorectal Carcinoma

Authors: Atsushi Nanashima, MD, Kenichirou Shibata, MD, Toshiyuki Nakayama, MD, Syuuichi Tobinaga, MD, Masato Araki, MD, Masaki Kunizaki, MD, Hiroaki Takeshita, MD, Shigekazu Hidaka, MD, Terumitsu Sawai, MD, Takeshi Nagayasu, MD, Toru Yasutake, MD

Published in: Annals of Surgical Oncology | Issue 8/2009

Abstract

Background

Microvessel count (MVC) has been correlated with patient prognosis in hepatocellular carcinoma. We investigated whether MVC assessed by staining with CD34 antibody was associated with disease-free and overall survival in patients with metastatic liver cancer (MLC).

Methods

We examined relationships between MVC and clinicopathologic factors or postoperative outcomes in 139 MLC patients who underwent hepatectomy between 1990 and 2006. CD34 expression was analyzed by the immunohistochemical method.

Results

MVC was associated with fibrous pseudocapsular formation on histological examination. By means of the modern Japanese classification of liver metastasis, poorer survival was associated with higher score, poorly differentiated adenocarcinoma, higher preoperative carcinoembryonic antigen (CEA) level, fibrous pseudocapsular formation, and smaller surgical margin. Shorter disease-free survival was associated with higher score when the Japanese classification of liver metastasis was used, multiple or bilobar tumor, regional lymph node metastasis in primary colon carcinoma, preoperative CEA level, fibrous pseudocapsular formation, and smaller surgical margin (<5 mm). Higher MVC (≥406/mm²) was associated with decreased disease-free and overall survival by univariate analysis (P = .034 and P = .021, respectively), and higher MVC represented an independently poor prognostic factor in overall survival by Cox multivariate analysis (risk ratio, 2.71; P = .023) in addition to histological differentiation.

Conclusions

Tumor MVC seems to be a useful prognostic marker of MLC patient survival.

Jaeck D, Oussoultzoglou E. Intrahepatic lymphatic invasion independently predicts poor survival and recurrences after hepatectomy in patients with colorectal carcinoma liver metastases. Ann Surg Oncol. 2007;14:3297–8.PubMedCrossRef

Kato T, Yasui K, Hirai T, et al. herapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46(Suppl):S22–31.PubMed

Sasaki A, Iwashita Y, Shibata K, et al. Analysis of preoperative prognostic factors for long-term survival after hepatic resection of liver metastasis of colorectal carcinoma. J Gastrointest Surg. 2005;9:374–80.PubMedCrossRef

Kokudo N, Miki Y, Sugai S, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg. 2002;137:833–40.PubMedCrossRef

Nanashima A, Yamaguchi H, Sawai T, et al. Expression of adhesion molecules in hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol. 1999;14:1004–9.PubMedCrossRef

Molleví DG, Serrano T, Ginestà MM, et al. utations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis. 2007;28:1241–6.PubMedCrossRef

Saad RS, Kordunsky L, Liu YL, et al. Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol. 2006;19:1317–23.PubMedCrossRef

Tanaka K, Shimada H, Fujii Y, et al. Pre-hepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver. Langenbecks Arch Surg. 2004;389:371–9.PubMedCrossRef

Onogawa S, Kitadai Y, Tanaka S, et al. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci. 2004;95:32–9.PubMedCrossRef

10.

Barozzi C, Ravaioli M, D’Errico A, et al. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer. 2002;94:647–57.PubMedCrossRef

11.

Ito K, Hibi K, Ando H, et al. Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma. Jpn J Clin Oncol. 2002;32:54–8.PubMedCrossRef

12.

Thelen A, Scholz A, Benckert C, et al. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. Int J Cancer. 2008;122:2471–81.PubMedCrossRef

13.

Ueda T, Oda T, Kinoshita T, et al. Neovascularization in pancreatic ductal adenocarcinoma: microvessel count analysis, comparison with non-cancerous regions and other types of carcinomas. Oncol Rep. 2002;9:239–45.PubMed

14.

Pang RW, Joh JW, Johnson PJ, et al. Biology of hepatocellular carcinoma. Ann Surg Oncol. 2008;15:962–71.PubMedCrossRef

15.

Sun B, Zhang S, Zhang D, et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep. 2006;16:693–8.PubMed

16.

Nanashima A, Ito M, Sekine I, et al. Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers. Dig Dis Sci. 1998;43:2634–40.PubMedCrossRef

17.

Nanashima A, Yamaguchi H, Sawai T, et al. Prognostic factors in hepatic metastases of colorectal carcinoma: immunohistochemical analysis of tumor biological factors. Dig Dis Sci. 2001;46:1623–8.PubMedCrossRef

18.

Japanese Society for Cancer of the Colon and Rectum. 3.2.2.H. In: Mutoh T, editor. General rules for clinical and pathological studies on cancer of the colon, rectum and anus (in Japanese). 7th ed. Tokyo: Kanehara; 2006. p. 14–5.

19.

Takeda A, Stoeltzing O, Ahmad SA, et al. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol. 2002;9:610–6.PubMedCrossRef

20.

Nash AD, Baca M, Wright C, Scotney PD. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm Pharmacol Ther. 2006;19:61–9.PubMedCrossRef

21.

Takeda A, Shimada H, Imaseki H, et al. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep. 2000;7:333–8.PubMed

22.

Nanashima A, Yoshinaga M, Yamaguchi H, et al. An immunohistochemical study of tumor vascularity and proliferation activity in cholangiocellular carcinoma: relationship to clinicopathologic factors and prognosis after hepatic resection. Acta Med Nagasaki. 2003;48:23–7.

23.

Fortner JG, Silva JS, Golbey RB, et al. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg. 1984;199:306–16.PubMedCrossRef

24.

Iwatsuki S, Esquivel CO, Gordon RD, et al. Liver resection for metastatic colorectal cancer. Surgery. 1986;100:804–10.PubMed

25.

Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254–62.PubMedCrossRef

26.

Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg. 1997;84:977–80.PubMedCrossRef

27.

Cady B, Jenkins RL, Steele GD Jr, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg. 1998;227:566–71.PubMedCrossRef

28.

Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.PubMedCrossRef

29.

Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231:487–99.PubMedCrossRef

30.

Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.PubMedCrossRef

31.

Nagashima I, Takada T, Matsuda K, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg. 2004;11:79–83.PubMedCrossRef

32.

Korita PV, Wakai T, Shirai Y, et al. Intrahepatic lymphatic invasion independently predicts poor survival and recurrences after hepatectomy in patients with colorectal carcinoma liver metastases. Ann Surg Oncol. 2007;14:3472–80.PubMedCrossRef

33.

Okano K, Yamamoto J, Kosuge T, et al. Fibrous pseudocapsule of metastatic liver tumors from colorectal carcinoma. Clinicopathologic study of 152 first resection cases. Cancer. 2000;89:267–75.PubMedCrossRef

34.

Miyagawa S, Miwa S, Soeda J, et al. Morphometric analysis of liver macrophages in patients with colorectal liver metastasis. Clin Exp Metastasis. 2002;19:119–25.PubMedCrossRef

35.

Harada Y, Ogata Y, Shirouzu K. Expression of vascular endothelial growth factor and its receptor KDR/Flk-1 as prognostic factors in human colorectal cancer. Int J Clin Oncol. 2001;6:221–8.PubMedCrossRef

36.

Rajaganeshan R, Prasad R, Guillou PJ, et al. The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer. 2007;96:1112–7.PubMedCrossRef

37.

Neal CP, Garcea G, Doucas H, et al. Molecular prognostic markers in resectable colorectal liver metastases: a systematic review. Eur J Cancer. 2006;42:1728–43.PubMedCrossRef

38.

Chan LS, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis. Anticancer Res. 2007;27:2317–23.PubMed

39.

Duff SE, Jeziorska M, Rosa DD, et al. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer. 2006;42:112–7.PubMedCrossRef

40.

Board RE, Valle JW. Metastatic colorectal cancer: current systemic treatment options. Drugs. 2007;67:1851–67.PubMedCrossRef

41.

Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007;11:1–128.PubMed

Title: Clinical Significance of Microvessel Count in Patients with Metastatic Liver Cancer Originating from Colorectal Carcinoma
Authors: Atsushi Nanashima, MD
Kenichirou Shibata, MD
Toshiyuki Nakayama, MD
Syuuichi Tobinaga, MD
Masato Araki, MD
Masaki Kunizaki, MD
Hiroaki Takeshita, MD
Shigekazu Hidaka, MD
Terumitsu Sawai, MD
Takeshi Nagayasu, MD
Toru Yasutake, MD
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 8/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-009-0459-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical Significance of Microvessel Count in Patients with Metastatic Liver Cancer Originating from Colorectal Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2009

Evolving Treatment Strategies for Gallbladder Cancer

Erratum—Pancreaticoduodenectomy and Vascular Resection: Persistent Controversy and Current Recommendations

Is There a Role for Intraoperative Radiation Therapy in Patients with Resected Pancreatic Adenocarcinoma?

The Number of Lymph Nodes Involved with Metastatic Disease Does Not Affect Outcome in Melanoma Patients as Long as All Disease Is Confined to the Sentinel Lymph Node

A Prospective Trial Comparing 1% Lymphazurin vs 1% Methylene Blue in Sentinel Lymph Node Mapping of Gastrointestinal Tumors

Colorectal Cancer Screening Among First-Degree Relatives of Colorectal Cancer Patients: Benefits and Barriers